Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881846 | 0.91 | PTPN1 (0.46) | PTPN1PTPN5POLBPPARGMMP3 | |
| SCHEMBL5881848 | 0.91 | PTPN1 (0.46) | PTPN1PTPN5POLBPPARGMMP3 | |
| SCHEMBL5882026 | 0.88 | POLB (0.50) | PTPN1PTPN5POLBMMP3MMP7 | |
| SCHEMBL5881755 | 0.88 | PTPN1 (0.48) | PTPN1PPARGCNR1GABRA5MAPT | |
| SCHEMBL5882152 | 0.84 | MAPT (0.49) | PTPN1PTPN5POLBPPARGCNR1 | |
| SCHEMBL6305504 | 0.82 | PTPN1 (0.57) | PTPN1POLBPPARGGABRA5 | |
| SCHEMBL6299617 | 0.82 | PTPN1 (0.57) | PTPN1POLBPPARGMMP3MMP7 | |
| SCHEMBL6134778 | 0.81 | MCL1 (0.41) | PTPN1PTPN5POLBPPARGCNR1 | |
| SCHEMBL5882270 | 0.80 | PPARG (0.39) | PTPN1PTPN5PPARGMMP3MMP7 | |
| SCHEMBL5881774 | 0.80 | PPARG (0.43) | PTPN1PTPN5PPARGCNR1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1132087-A1 | REMEDIES FOR POLYCYSTIC OVARY SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | PTPN1 3024/4885PTPN5 2703/4885POLB 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.